Future MCH drug development efforts, whether focused on an application in sleep disorders or on any other functions of the MCH system, will likely need to contend with many of the same issues faced during the development of MCHR1 antagonists for obesity. The gene discussed is MCHR1; the disease is obesity due to melanocortin 4 receptor deficiency.